Pharmacotherapy of type 2 diabetes: An update
Jagriti Upadhyay(VA Boston Healthcare System), Christos S. Mantzoros(Beth Israel Deaconess Medical Center), Eun Seok Kang(Yonsei University), Stergios A. Pοlyzos(Aristotle University of Thessaloniki), Kyung‐Hee Park(Dongguk University), Stavroula Α. Paschou(Beth Israel Deaconess Medical Center), Jochen Seufert(University of Freiburg), Niki Katsiki(Neurosciences Institute), Asterios Karagiannis(Hippocration General Hospital), Elliot Sternthal(VA Boston Healthcare System), Patricia Underwood(VA Boston Healthcare System), Bindiya Thakkar(Beth Israel Deaconess Medical Center), Nikolaos Perakakis(Deutsches Diabetes-Zentrum e.V.)
Cited by 187
Related Papers
Role of leptin in the neuroendocrine response to fasting
|Nature|1996|3.1k
Adverse metabolic and cardiovascular consequences of circadian misalignment
|Proceedings of the National Academy of Sciences|2009|2.3k
Obesity and cancer risk: Emerging biological mechanisms and perspectives
|Metabolism|2018|1.6k
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
|Metabolism|2018|1.2k